Search research articles
Contact Us
Filters
Showing results (111-120 of 266) with videos related to
Page
of 27
Sort By:
Clinical Neuropharmacology
|
January 30, 2023
The Clinical Development of Levodopa Inhalation Powder
Robert A Hauser, Peter A LeWitt, Cheryl H Waters, et al.
Clinical Neuropharmacology
|
October 7, 2008
Levetiracetam for stiff-person syndrome: report of 2 patients
W Reed Shimberg, Neha B Patel, Kelly L Sullivan, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 1, 2016
Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial
Daniel Weintraub, Robert A Hauser, Jordan J Elm, et al.
Parkinsonism & Related Disorders
|
March 17, 2022
Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine
Robert A Hauser, Hadas Barkay, Amanda Wilhelm, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 6, 2005
Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease
Kelly L Sullivan, Joseph F Staffetti, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
June 15, 2005
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
Theresa A Zesiewicz, Kelly L Sullivan, John L Maldonado, et al.
BMC Neurology
|
June 9, 2016
Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease
Robert A Hauser, Jaroslaw Slawek, Paolo Barone, et al.
Neuropsychology
|
September 22, 2010
The independent influence of apathy and depression on cognitive functioning in Parkinson's disease
London C Butterfield, Cynthia R Cimino, Lynn E Oelke, et al.
The International Journal of Neuroscience
|
September 7, 2013
Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients
Rajeev Kumar, Robert A Hauser, Joseph Mostillo, et al.
Advances in Therapy
|
March 10, 2022
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease
Robert A Hauser, Nir Giladi, Werner Poewe, et al.
Page
of 27
Search research articles
Search
Showing results (111-120 of 266) with videos related to
Sort By:
Page
of 27
Clinical Neuropharmacology
|
January 30, 2023
The Clinical Development of Levodopa Inhalation Powder
Robert A Hauser, Peter A LeWitt, Cheryl H Waters, et al.
Clinical Neuropharmacology
|
October 7, 2008
Levetiracetam for stiff-person syndrome: report of 2 patients
W Reed Shimberg, Neha B Patel, Kelly L Sullivan, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
April 1, 2016
Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial
Daniel Weintraub, Robert A Hauser, Jordan J Elm, et al.
Parkinsonism & Related Disorders
|
March 17, 2022
Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine
Robert A Hauser, Hadas Barkay, Amanda Wilhelm, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 6, 2005
Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease
Kelly L Sullivan, Joseph F Staffetti, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
June 15, 2005
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
Theresa A Zesiewicz, Kelly L Sullivan, John L Maldonado, et al.
BMC Neurology
|
June 9, 2016
Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease
Robert A Hauser, Jaroslaw Slawek, Paolo Barone, et al.
Neuropsychology
|
September 22, 2010
The independent influence of apathy and depression on cognitive functioning in Parkinson's disease
London C Butterfield, Cynthia R Cimino, Lynn E Oelke, et al.
The International Journal of Neuroscience
|
September 7, 2013
Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients
Rajeev Kumar, Robert A Hauser, Joseph Mostillo, et al.
Advances in Therapy
|
March 10, 2022
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease
Robert A Hauser, Nir Giladi, Werner Poewe, et al.
Page
of 27